Company news

Neurizon Therapeutics Limited news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Non-Renounceable Rights Offer

February 17, 2019

PAA Completes Successful Taste Mask Testing of New Tablet

February 10, 2019

PharmAust Signs Agreement for US Phase I Trials in Dogs

February 6, 2019

PharmAust Completes Scaled Manufacture of Monepantel Tablets

February 6, 2019

PharmAust Appendix 4C and Shareholders Update

January 31, 2019

PharmAust and Elanco Execute Data Sharing Agreement

January 28, 2019

Optimisation of Monepantel Uptake

January 20, 2019

Monepantel Principal Metabolite Shows Anti-Cancer Activity

January 13, 2019

PharmAust Develops Method for MPL/Analogue Manufacture

December 2, 2018

GMP Tablet Manufacture Commences for Canine Clinical Trials

November 12, 2018

Appendix 4C & Company Update - Sep 2018

October 31, 2018

PharmAust Develops GMP Method for Monepantel Analogues

October 28, 2018

PharmAust Progresses Monepantel Tablet Program for Cancer

October 14, 2018

Olivia Newton-John Cancer Reseach Institute collaboration

September 10, 2018

Reformulation of MPL into tablet form for upcoming trials

September 3, 2018

Appendix 4C & Company Update - June 18

July 31, 2018

Epichem gains prestigious international ISO accreditation

July 1, 2018

Epichem Awarded Major US Drug Discovery Contract Extension

June 6, 2018

MPL successfully reformulated for canine clinical trials

May 27, 2018

Chief Executive Officer resigns

May 21, 2018

Appendix 4C & Company Update

April 30, 2018

PharmAust enters option to license agreement with Elanco

April 18, 2018

Appendix 4D and Half Yearly Report & Accounts

February 28, 2018

PharmAust receives $354k R&D Tax Incentive Refund

February 27, 2018

Appendix 4C - Quarterly Report & Shareholders Update

January 30, 2018

Monepantel reformulation successfully improves dose & taste

January 29, 2018

Epichem Awarded One Year Contract Extension from DNDi

January 17, 2018

Phase II Dog Lymphoma Trial Confirms MPL Clinical Benefit

December 12, 2017

PharmAust Raises $1.873m via an Oversubscribed Placement

December 5, 2017

New MPL analogues show greater anti-cancer activity

November 22, 2017

New drugs patented for cancer in USA

November 15, 2017

Epichem Update - progress on milestones and revenue targets

October 31, 2017

Appendix 4C - Quarterly Report & Brief Company Update

October 26, 2017

Monepantel reformulation project continues to progress

October 16, 2017

New patent secured in US for non-cancer applications

October 9, 2017

Reformulation project achieves first milestones and on-track

September 19, 2017

PharmAust secures core Europe patent

September 11, 2017

PharmAust & Nihon Nohyaku Japan Enter Assignment Agreement

September 3, 2017

Appendix 4E & Full Year Statutory Accounts 2017

August 31, 2017

PharmAust Shareholders Update

August 21, 2017

Epichem reports record $3m revenues & expands laboratory

July 16, 2017

Canadian-based specialists to reformulate monepantel

June 27, 2017

New European patent granted for non-cancer applications

June 7, 2017

PharmAust secures core patent in Japan

June 5, 2017

Phase II trial prelim results demonstrate clinical benefit

May 18, 2017

New patent granted for non-cancer applications

May 16, 2017

PharmAust secures core China patent

May 4, 2017

Appendix 4C - Quarterly Report & Company Update - March 2017

April 13, 2017

Dr Richard Hopkins Appointed as CEO of PharmAust

February 28, 2017

Appendix 4D & Financial Report - Dec 2016

February 28, 2017

← Newer news releases · Older news releases →

Decks

The 5 newest of 36 decks. Every deck is listed under its year.